Baseline Screening Tests Before JAK Inhibitor Therapy for Alopecia Areata
Before initiating JAK inhibitor therapy in a patient with autoimmune alopecia, you must perform: complete blood count with differential, comprehensive metabolic panel (liver and renal function tests), lipid panel, tuberculosis screening (T-SPOT or QuantiFERON with chest imaging if positive), hepatitis B and C serology, HIV testing, and syphilis screening (TPPA), along with baseline skin examination for malignancy risk. 1, 2
Required Laboratory Tests
The 2025 expert consensus on JAK inhibitors provides the framework for baseline screening 1:
Core Laboratory Panel
- Complete blood count with differential - Essential for baseline hematologic assessment
- Liver function tests (AST/ALT at minimum, though full panel including bilirubin, albumin, alkaline phosphatase, and GGT is comprehensive)
- Renal function tests (creatinine, BUN)
- Lipid panel - JAK inhibitors can affect lipid metabolism
Infectious Disease Screening
Real-world data from 218 alopecia areata patients demonstrates the critical importance of infectious screening 2:
- Tuberculosis: 37 of 218 patients (17%) had positive T-SPOT testing or chest imaging findings suggesting TB - this is a substantial proportion requiring screening
- Hepatitis B surface antigen: 10 of 218 patients (4.6%) were positive
- Hepatitis C antibodies: Screen all patients
- HIV antibody: Screen all patients
- Syphilis (TPPA): 3 of 218 patients (1.4%) were positive
- Thyroid function (TSH): 9 of 176 tested patients (5.1%) had abnormalities - particularly relevant given autoimmune comorbidity patterns
Risk Factor Assessment
Beyond laboratory tests, document specific risk factors 1:
Cardiovascular and Thrombotic Risk
- History of venous thromboembolism (VTE) - distinguish provoked vs. unprovoked events
- Prior cardiovascular events (MI, stroke)
- Smoking history - increases both cardiovascular and malignancy risk, particularly lung cancer
- Age >50 years with cardiovascular risk factors (relevant from ORAL Surveillance trial subanalyses)
Malignancy Screening
- Baseline skin examination for non-melanoma skin cancer, especially in high-risk patients
- Document smoking history for lung cancer risk stratification
Other Considerations
- History of herpes zoster - JAK inhibitors increase reactivation risk
- History of complicated diverticulitis
- Hepatitis B core antibody if surface antigen negative (for reactivation risk)
Monitoring Schedule
After baseline screening, establish periodic monitoring 1:
- CBC with differential, liver/renal tests, lipids at regular intervals (specific frequency depends on individual risk factors and institutional protocols)
- Skin examinations per national recommendations (not necessarily annual - adjust to local risk profiles)
- Do NOT rely on CRP/ESR for disease activity monitoring, as JAK inhibitors suppress IL-6 signaling and artificially lower these markers independent of true disease control
Critical Pitfalls to Avoid
- Incomplete TB screening: With 17% positivity rate in real-world AA cohorts, this cannot be skipped 2
- Missing hepatitis B screening: Reactivation risk is real and preventable with proper screening
- Overlooking thrombotic risk factors: The ORAL Surveillance trial highlighted VTE concerns, making this assessment non-negotiable 1
- Inadequate smoking history: Affects both cardiovascular and malignancy risk stratification
- Using CRP/ESR for treatment response: These will decrease regardless of clinical improvement due to IL-6 pathway inhibition 1
The evidence strongly supports comprehensive baseline screening before JAK inhibitor initiation in alopecia areata patients, with particular emphasis on infectious disease screening given the real-world prevalence of latent infections in this population 2.